Abstract:
The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is
determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin
secretion insufficiency. With this purpose theare can be utilized sulphonylureics (glyclazide,
glypizide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide,
mitiglynide), thyazolidindiones (pioglytazone, balaglyztazone, rivoglitazone etc.), dual/pan
PPAR modulators ( tesaglitazar, muraglitazar, aleglitazar, chiglitazar etc.), tetrazaharides
(acarboze, vogliboze etc.), GLP-1 agonists (exenatide, exenatide LAR, liraglutide, albiglutide
etc.), DPP-IV antagonists and blockers (sitaglypide, vildaglyptide, saxaglyptine, aloglyptine),
amilines analogues (pramlintid), selective sodium glucose cotransporter-2 inhibitors
(dapagliflozin, canagliflozin, empagliflozin etc.), 11-beta-hydroxysteroid dehydrogenase type 1
inhibitors (INCB13739), situins (resveratrol etc.), AMP-activated protein kinase (imeglimin
etc.), glucokinase activators (piragliatin etc.), agonists D2-receptors (bromcriptine), bile acid
sequestrants (coleselevam) etc..
Selectarea raţională a antidiabeticelor orale în tratamentul diabetului zaharat tip 2 este
determinată de influenţa asupra verigelor patogenetice, combaterea insulinorezistenţei şi
insuficienţei secreţiei insulinei. Cu acest svop se pot utiliza: sulfonilureicele (gliclazida,
glipizida, glimepirida etc.), biguanidele (metformina), meglitinidele (repaglinida, nateglinida,
mitiglinida), tiazolidindionele (pioglitazon, balaglitazon, rivoglitazon etc.), modulatorii bi-şi pan
ai PPAR receptorilor (tesaglitazar, muraglitazar, aleglitazar, cicglitazar etc.), tetrazaharidele
(acarboza, vogliboza etc.), agoniştii GLP-1 (exenatid, exenatid LAR, liraglutid, albiglutid etc.),
antagoniştii sau blocantele DPP-IV (sitagliptina, vildagliptina, saxagliptina, alogliptina etc.),
analogii amilinei (pramlintid), inhibitorii sodiu-glucoză cotransportorului 2 (dalagliflozin,
canagliflozin, empagliflozin etc.), inhibitorii 11-beta-hidroxisteroid dehidrogenazei 1
(INCB13739), sirtuinele (resveratrol etc.), activatorii AMP-protein kinazei (imeglimin etc.),
activatorii glucokinazei (piragliatin etc.), agoniştii D2-receptorilor (bromocriptina etc.),
sechestranţii acizilor biliari (coleselevam etc.) etc..
